Article
Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma
Search Medline for
Authors
Published: | April 4, 2012 |
---|
Outline
Text
The purpose of this study is to develop a specific and efficient targeted gene therapy approach for laryngeal carcinomas. Several promoters were cloned and evaluated for transcription regulation potential. One SLPI promoter fragment (-650 to +22) showed the highest efficiency and specificity among the promoters of SCCA2, SLPI(-849 to +22, -531 to +22)and survivin in laryngeal carcinoma Hep-2 cells, and was used for expression control of an active recombinant caspases-3 (revCasp3). Adenoviral vector was constructed (Ad-SLPI-revCasp3), and antitumor efficacy was assessed in vitro and in vivo. RevCasp3 was successfully expressed in Hep-2 cells with efficient activation of endogenous Caspase-3, leading to specific apoptosis of Hep-2 cells when compared to the control normal HuVEC cells. In laryngeal carcinoma xenograft model in nude mice, intratumoral administration of Ad-SLPI-revCasp3 significantly inhibited tumor growth, without any obvious toxicity. In summary, the specific and efficient apoptosis-inducing potential of Ad-SLPI-revCasp3 makes it a new approach of targeted gene therapy for laryngeal squamous cell carcinoma